IL283481A - A new crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1h-imidazol-5-yl]-7-[5-chloro-2-(1h -tetrazol-1-yl)phenyl]-3,2-dihydroindolizin-5(1h)-one - Google Patents

A new crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1h-imidazol-5-yl]-7-[5-chloro-2-(1h -tetrazol-1-yl)phenyl]-3,2-dihydroindolizin-5(1h)-one

Info

Publication number
IL283481A
IL283481A IL283481A IL28348121A IL283481A IL 283481 A IL283481 A IL 283481A IL 283481 A IL283481 A IL 283481A IL 28348121 A IL28348121 A IL 28348121A IL 283481 A IL283481 A IL 283481A
Authority
IL
Israel
Prior art keywords
dihydroindolizin
fluoropyridin
tetrazol
imidazol
fluoro
Prior art date
Application number
IL283481A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL283481A publication Critical patent/IL283481A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL283481A 2018-11-30 2021-05-26 A new crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1h-imidazol-5-yl]-7-[5-chloro-2-(1h -tetrazol-1-yl)phenyl]-3,2-dihydroindolizin-5(1h)-one IL283481A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018224434 2018-11-30
PCT/JP2019/046893 WO2020111268A1 (ja) 2018-11-30 2019-11-29 （３ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１ｈ）－オンの新規結晶

Publications (1)

Publication Number Publication Date
IL283481A true IL283481A (en) 2021-07-29

Family

ID=70853323

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283481A IL283481A (en) 2018-11-30 2021-05-26 A new crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1h-imidazol-5-yl]-7-[5-chloro-2-(1h -tetrazol-1-yl)phenyl]-3,2-dihydroindolizin-5(1h)-one

Country Status (16)

Country Link
US (1) US20210395250A1 (enExample)
EP (1) EP3888653A4 (enExample)
JP (1) JP7196931B2 (enExample)
KR (1) KR20210097119A (enExample)
CN (1) CN113226312A (enExample)
AU (1) AU2019390094A1 (enExample)
BR (1) BR112021010476A2 (enExample)
CA (1) CA3121447A1 (enExample)
IL (1) IL283481A (enExample)
MX (1) MX2021006147A (enExample)
NZ (1) NZ776666A (enExample)
PH (1) PH12021551219A1 (enExample)
SG (1) SG11202105697SA (enExample)
TW (1) TWI826599B (enExample)
WO (1) WO2020111268A1 (enExample)
ZA (1) ZA202103692B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240108639A1 (en) * 2020-12-11 2024-04-04 Board Of Regents, The University Of Texas System Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
JP2024125436A (ja) * 2021-07-20 2024-09-19 小野薬品工業株式会社 イミダゾール化合物の製造方法
TWI833610B (zh) * 2022-03-21 2024-02-21 大陸商上海濟煜醫藥科技有限公司 三并環類化合物製備方法及其中間體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794597B1 (en) 2011-12-21 2017-11-15 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
JP2016093285A (ja) 2014-11-13 2016-05-26 株式会社ユニバーサルエンターテインメント 遊技機
EP3231803B1 (en) * 2014-12-10 2020-07-01 ONO Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
SG11202105697SA (en) 2021-06-29
ZA202103692B (en) 2023-03-29
PH12021551219A1 (en) 2021-11-08
TWI826599B (zh) 2023-12-21
TW202039485A (zh) 2020-11-01
CA3121447A1 (en) 2020-06-04
KR20210097119A (ko) 2021-08-06
CN113226312A (zh) 2021-08-06
NZ776666A (en) 2024-11-29
JP7196931B2 (ja) 2022-12-27
EP3888653A4 (en) 2022-08-24
MX2021006147A (es) 2021-06-23
BR112021010476A2 (pt) 2021-08-24
WO2020111268A1 (ja) 2020-06-04
EP3888653A1 (en) 2021-10-06
AU2019390094A1 (en) 2021-06-17
JPWO2020111268A1 (ja) 2021-10-14
US20210395250A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
SG11202111404XA (en) Bicyclic compounds
SG11202013064WA (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
SG11202104206SA (en) New heterocyclic compounds
EP4037688A4 (en) ANTIVIRAL HETEROCYCLIC COMPOUNDS
IL283481A (en) A new crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1h-imidazol-5-yl]-7-[5-chloro-2-(1h -tetrazol-1-yl)phenyl]-3,2-dihydroindolizin-5(1h)-one
EP3548496A4 (en) CONDENSED PYRIMIDINE COMPOUNDS AS DUAL BRD4 AND JAK2 INHIBITORS AND METHOD FOR USE THEREOF
EP3919055A4 (en) HETEROCYCLIC COMPOUND
SMT202300384T1 (it) Composti di pirimidina fusi come modulatori di kcc2
SI3448848T1 (sl) Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
IL289617A (en) Heterocyclic compounds
EP3303341A4 (en) Fused tricyclic heterocyclic compounds useful for treating hiv infection
IL290367A (en) Fused ring heteroaryl compounds as ripk1 inhibitors
EP3768627A4 (en) Reconstitution of independent beverage flows
SG11202101499UA (en) Heterocyclic compounds as ahr modulators
IL288987A (en) New heterocyclic compounds
IL273237A (en) Novel heterocyclic compounds as MGLUR7 modulators
PL3613436T3 (pl) Doustna zawiesina temozolomidu
EP3858838A4 (en) Heterocyclic compound
GB201915191D0 (en) Novel heterocyclic compounds
GB201806488D0 (en) Heterocyclic TADF compounds
HK40109453A (zh) 杂环化合物
HK40110226A (zh) 稠环化合物
HK40109856A (zh) 稠环化合物
HK40110213A (zh) 稠环化合物
HK40079682A (en) Novel heterocyclic compounds